AstraZeneca and Covington Fail Again in Effort to Stop Generic Seroquel

, The Litigation Daily

   |0 Comments

The Food and Drug Administration didn't improperly approve 11 generic versions of AstraZeneca's Seroquel in March, according to a ruling by U.S. District Judge Beryl Howell of the District of Columbia. Sales of the drug--which is used to treat schizophrenia and bipolar disorder--topped $3 billion in the U.S. last year.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202562095561

Thank you!

This article's comments will be reviewed.